Breyanzi (lisocabtagene maraleucel) / BMS - LARVOL DELTA

Early PET response for relapse prediction in 2nd or higher line lisocabtagen maraleucel in large B-cell lymphoma (ASH 2025) - "Early PET assessment in patients treated with liso-cel may have the potential to predict long-term remission and could influence early post-CART therapy decision with respect to response-adaption."

B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

Real-world data of lisocabtagene maraleucel as second line therapy for patients with large B-cell lymphoma: Updated Results of the french descar-T registry by lysa (ASH 2025) - P | "These preliminary results indicate that liso-cel as 2L treatment for R/R LBCL is feasible and safe in Frenchcenters. Although follow-up is still short, early response rates and toxicities are consistent with thoseseen in the TRANSFORM trial, including CR rates above 70%. Liso-cel exhibits a favorable safety profile,with very few cases of severe CRS or neurotoxicity, less than 5% requiring ICU transfer, and only onedeath related to infection."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

Rehabilitation needs and clinical associations post CAR T-cell therapy: A retrospective analysis (ASH 2025) - "CAR-T products included axi-cel (n=52), tisa-cel(n=7), liso-cel (n=29), and brexu-cel (n=11). 99 lymphoma patients were included, with a median age at collection of 65 years (age range 24-81). 58% were female. Lymphoma subtypes included diffuse large B-cell lymphoma (n=78), follicularlymphoma (n=10), and mantle cell lymphoma (n=11)."

CAR T-Cell Therapy • Retrospective data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma

Optimizing immunity to pneumococcus by vaccination with pneumococcal 13-valent conjugate vaccine before and after CD19-targeted CAR T cell immunotherapy (ASH 2025) - "CAR-T products used were axicabtagene ciloluecel (65%), lisocabtagene maraleucel(20%), brexucabtagene autoleucel (10%) and tisagenlecleucel (5%). PCV13 vaccination before and after CAR-T is safe but provides limited and transientpneumococcal immunity in this immunocompromised population. Ongoing translational work isevaluating if the strategy induced cellular immunity against the CRM adjuvant included in PCV13. Thesefindings support the need to explore alternative strategies like IVIG to enhance protective immunity inCAR-T recipients."

CAR T-Cell Therapy • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Pneumococcal Infections

Safety and efficacy of transposon, BAFF-ligand directed chimeric antigen receptor T cells (LMY-920) with pre-apheresis obinutuzumab for patients with Relapsed/Refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (ASH 2025) - P1 | "Anti-CD19 CAR T cells show modestactivity in CLL, with lisocabtagene maraleucel demonstrating only 57% overall response and 18%complete response rates in BTK/BCL2 inhibitor-treated patients...Key exclusion criteriainclude CNS involvement, active malignancy, cardiovascular instability, active infection, and autoimmunedisease requiring immunosuppression.The treatment protocol involves: (1) pre-apheresis B cell depletion with obinutuzumab (100mg day 1,900mg day 2) starting 14-21 days before leukapheresis; (2) standard leukapheresis and LMY-920manufacturing over 8-11 days using transposon technology; (3) lymphodepletion with fludarabine (30mg/m²/day) and cyclophosphamide (500 mg/m²/day) for 3 days beginning on day -5; and (4) LMY-920infusion on day 0 at escalating doses from 2×10⁶ to 8×10⁶ BAFF CAR-T cells/kg... Targeting ubiquitously expressed BAFF receptors with optimization of the starting T cellmaterial through pre-apheresis B cell depletion for..."

CAR T-Cell Therapy • Clinical • IO biomarker • Chronic Lymphocytic Leukemia • Gene Therapies • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Small Lymphocytic Lymphoma

Parkinsonism after treatment with anti-CD19 CAR-T: Case report, institutional data review, and pharmacovigilance analysis of the FDA adverse event reporting system database (ASH 2025) - "Patients received Yescarta (n=8), Breyanzi (n=3), andTectarus (n=1)...Treatment included dexamethasone (n=10) and anakinra (n=6).Symptoms resolved in the majority (83%).We furthermore investigated nervous system adverse events (NSAE) associated with FDA-approved CD19CAR-T reported in the FAERS database between January 2017 and March 2025...Our report of parkinsonism after CD19 CAR-T suggests that CAR-T induced parkinsonism may not beunique to BCMA CAR-T and may be caused by an additional or separate mechanism of which furtherstudy is warranted. Review of our institutional database and FAERS suggests these symptoms may becommon but underreported in the literature. Our findings support the need for further closeneurological monitoring in patients after treatment with CD19 CAR-T."

Adverse events • Case report • Clinical • IO biomarker • Review • Alzheimer's Disease • Ataxia • B Cell Lymphoma • CNS Disorders • Cognitive Disorders • Developmental Disorders • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Movement Disorders • Non-Hodgkin’s Lymphoma • Parkinson's Disease • Splenic Marginal Zone Lymphoma • ROR1

Outcomes of CD20xCD3 bispecific antibody therapy as holding or bridging therapy prior to chimeric antigen receptor T-cell infusion in aggressive B-cell lymphomas (ASH 2025) - "Glofitamab was used in12 patients (75%) and epcoritamab in 4 (25%).Of the 16 patients, three (18%) died before CAR-T due to rapid disease progression, and 2 (13%) declinedCAR-T due to ongoing BiAbs response. Eleven (69%) proceeded to CAR-T with axicabtagene ciloleucel(n=8), lisocabtagene maraleucel (n=2), or brexucabtagene autoleucel (n=1)...This suggests that BsAb responsiveness may reflect an immunologicallypermissive tumor microenvironment predictive of efficacy, irrespective of the TCE platform. Thesefindings support further study of BsAb bridging as a functional biomarker of CAR-T responsiveness."

CAR T-Cell Therapy • IO biomarker • B Cell Lymphoma • CNS Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma

The relationship of social support and psychosocial complexity with chimeric antigen receptor T-cell therapy outcomes (ASH 2025) - "Aplurality of patients received liso-cel (29%), followed by tisa-cel (19%), axi-cel (18%), and ide-cel (13%). In a systematic social support analysis, a significant percentage of patients noted caregiveravailability issues and/or financial concerns. However, neither limited social support nor increasedpsychosocial complexity were associated with increased CAR-T toxicity or worse survival, underscoringthat psychosocial barriers should not limit access to CAR-T."

CAR T-Cell Therapy • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma

Patient-reported outcomes (PROs) with lisocabtagene maraleucel (liso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study (ASH 2025) - P2 | "In TRANSCEND FL, most patients with 3L+ R/R MZL experienced clinically meaningfulimprovements in PROs after liso-cel treatment, including symptom relief, enhanced functioning, andimproved QOL. The study represents one of the biggest efforts to characterize PROs in patients with 3L+R/R MZL and provides valuable insights into the patient experience following treatment with liso-cel. ThePRO results complement the clinical efficacy and safety profile of liso-cel in 3L+ R/R MZL, reinforcing itspotential to become standard of care in this setting."

Clinical • P2 data • Patient reported outcomes • Bone Marrow Transplantation • Fatigue • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma

BTKi in the peri-infusion period in lymphoma patients receiving CD19 CAR T cell therapy (ASH 2025) - "ResultsWe included 359 patients with a median age of 67 (IQR 58 – 73) at CAR T infusion (40% liso-cel, 36% axi-cel, 16% tisa-cel, and 8% brexu-cel) between 2016 and 2025...BTKi administered included ibrutinib (59%), zanubrutinib (21%), pirtobrutinib(14%), or acalabrutinib (6%)...Relative to CAR T cell therapy alone, the toxicity of combination treatmentwas comparable including grade 3+ CRS, heme toxicity, infections, bleeding, and arrhythmias. Our datalargely support the safety of bridging BTKi, though prospective validation is needed to substantiate ourfindings and to determine whether adding BTKi to CAR T is therapeutically advantageous."

CAR T-Cell Therapy • Clinical • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Malignancies • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Mantle Cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia

Lisocabtagene maraleucel (liso-cel) demonstrates superior efficacy across inflammatory risk subgroups in second-line (2L) large B-cell lymphoma (LBCL): A retrospective analysis of the TRANSFORM study (ASH 2025) - P1, P3 | "InflaMix is consistently prognostic in patients with LBCL treated with CAR T cell therapy inlater-line settings. However, in 2L LBCL, InflaMix stratified outcomes in patients treated with SOC, but notin those treated with liso-cel. The results from this study support prior data showing InflaMixstratification of patients treated with bispecific antibodies (Magno G, et al."

Retrospective data • B Cell Lymphoma • Hematological Malignancies • Inflammation • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • CRP

Rondecabtagene autoleucel, an autologous, dual-targeting CD19/CD20 CAR T-cell candidate manufactured from CD62L+ enriched T cells, achieves durable responses in patients with large B-cell lymphoma (ASH 2025) - P1/2 | "Following a standard 3-day LD regimen of fludarabine and cyclophosphamide, patients received a single dose of ronde-cel, in the outpatient or inpatient setting, at the recommended Phase 2 dose (RP2D) of 100 x 106 CAR cells...Grade 1 or 2 cytokine release syndrome (CRS) was reported in 62% (37/60) patients, with no ≥ Grade 3 CRS, and 42% (25/60) of all patients receiving tocilizumab...Grade ≥ 3 ICANS was reported in 13% (8/60) of patients, including 7% (1/15) of patients after the introduction of routine dexamethasone prophylaxis, and resolved promptly with standard therapy (median time to < Grade 3 was 2.5 days)... Ronde-cel achieved high overall response and complete response rates with an encouraging safety profile in high-risk patients with LBCL in a Phase 1/2 multi-center trial. Complete responses were durable, including 100% CR at ≥ 6 months among patients treated in the 2L setting. A single-arm pivotal trial of ronde-cel is ongoing in patients treated in..."

CAR T-Cell Therapy • Clinical • B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

Tumor mutational burden as a novel biomarker of resistance to CD19 CAR-T cell therapy in large B-cell lymphoma (ASH 2025) - "Its prognostic value in relapsed/refractory (R/R) LBCL and relevanceto CAR-T efficacy are unknown. We analyzed pre-treatment tumor biopsies from 119 patients with R/R LBCL treated withcommercial CAR-T (53% axicabtagene-ciloleucel, 17% lisocabtagene-maraleucel, 30% tisagenlecleucel; 8%2L, 48% 3L, 44% ≥4L). This is the first study to demonstrate that high TMB is an independent biomarker for pooroutcomes in R/R LBCL patients treated with CAR T-cell therapy, providing supplemental prognostic valueover tumor burden and inflammatory markers. This finding contrasts with the role of TMB as a favorablebiomarker for ICB. Our transcriptomic analysis suggests a potential mechanism involving attenuatedimmune-signaling in the tumor microenvironment, which may hinder CAR T-cell efficacy."

Biomarker • CAR T-Cell Therapy • IO biomarker • Tumor mutational burden • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • IL2 • STAT5 • TMB • TP53

Bispecific antibody vs non-bispecific antibody systemic therapy as immediate next line treatment after chimeric antigen receptor T-cell (CART) failure in large B-cell lymphoma (ASH 2025) - "Most common CART product was axi-cel (56%), followedby tisa-cel (21%), liso-cel (22%), and others (1%).73 pts received BsAbs ,with BsAb monotherapy (B-M) in 60 pts and BsAb + targeted therapy (B+T) in 13pts. Non-BsAb regimens (n=238) included chemoimmunotherapy (CIT, n=45), lenalidomide +/-tafasitamab (len +/-taf, n=75), polatuzumab-bendamustine-rituximab (pola-BR; n=48), checkpointinhibitors (CPI, n=25), loncastuximab (lonca, n=7) or other targeted therapies (TT, n=38).Baseline characteristics were balanced between the B-M and non-BsAb groups, including age, sex, cell oforigin, double-hit lymphoma (DHL), primary refractory disease to frontline CIT (PRD), prior autologoustransplant, prior bendamustine, and time to salvage <90 days post–CAR-T...Treatment-era bias may affect results, as manynon-BsAb pts were potentially treated before BsAb FDA approval, but our results support integration ofBsAbs in the post-CART setting. Prospective validation is warranted to define..."

CAR T-Cell Therapy • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

Predicting CAR T-cell therapy outcomes in large B-cell lymphoma using pre-infusion clinical and inflammatory markers: A machine learning approach with explainable artificial intelligence (ASH 2025) - "Of the1309 patients, 779 were included in the analysis after excluding those diagnosed with Mantle CellLymphoma (MCL), those receiving lisocabtagene maraleucel, or treated with CAR T in second line, andthose for whom PFS could not be computed. Eligible patients had Diffuse Large B-cell Lymphoma(DLBCL, n=508), Primary Mediastinal B-cell Lymphoma (PMBCL, n=85), High-Grade B-cell Lymphoma(HGBCL, n=126), or transformed Follicular Lymphoma (tFL, n=50), and received tisagenlecleucel (n=345) oraxicabtagene ciloleucel (n=431) as third-line therapy or beyond...Although externalvalidation performance was lower (C-index = 0.55), likely due to differences in follow-up (median follow-up 6 vs. 19 and 17 months in train and test sets, respectively) and censoring, the model showed stableresults on internal test data, providing support for its generalizability.ConclusionAn ML model based on a limited set of routinely available pre-leukapheresis variables (bulky disease,LDH, ASCT, Hb,..."

CAR T-Cell Therapy • Clinical • Machine learning • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Large B Cell Lymphoma • Lymphoma • Mantle Cell Lymphoma • Mediastinal B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Primary Mediastinal Large B-Cell Lymphoma

Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL (ASH 2025) - P2 | "In patients with 3L+ FL, a single infusion of liso-cel demonstrated remarkable efficacy, withdurable responses and high 3-year survival rates, regardless of POD24 status or prior bendamustineexposure. No new safety signals were identified. Grade ≥3 neutropenia and hypogammaglobulinemiadecreased over time and severe infections remained low, further underscoring the favorable long-termsafety profile of liso-cel in patients with 3L+ FL."

Clinical • Follicular Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia

Comparison of real-world survival outcomes and time toxicity of CAR T-cell versus bispecific antibody therapies in relapsed/refractory follicular lymphoma: A multicenter cohort from 15 US academic institutions (ASH 2025) - "MethodsWe conducted a multicenter retrospective study of adults with R/R grade 1-3A FL who received standard-of-care CAR-T (axi-cel, tisa-cel, liso-cel) or BsAb (mosunetuzumab, epcoritamab) in the third-line or latersetting before Jan 1, 2025. This study provides benchmark data for counselingpatients about expected time burden of CAR-T (51-64 days) and BsAb (36-38 days) over the first year ofthese therapies. Further, with superior PFS of CAR-T in this study and minimal impact of time toxicity onsurvival outcomes, these data can be used to better support shared decision-making in R/R FL byaddressing patient preferences regarding both contact days as well as duration of disease control."

Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma

A retrospective multi-center review of the safety and efficacy of bispecific T-cell engagers in the management of post-transplant lymphoproliferative disorder – the bite PTLD study (ASH 2025) - "Bispecificantibodies (BsAb) including glofitamab (glofit), epcoritamab (epcor) and mosunetuzumab (mosun) arerevolutionizing the treatment of B-cell lymphomas...Frontline, 5 received rituximab alone (1 PR, 1 CR), 3 DA-R-EPOCH (1 PR, 1 CR), 2 Pola-R-CHP (1 PR). 4 pts received CAR-T prior to BsAb (2 axi-cel, 2 liso-cel) with 3responses (1 CR, 2 PR) and median duration of response (DOR) 2.7 months (mo)...All were treated with dexamethasone +/- tocilizumab...Ourresults support investigation of BsAb as a therapeutic option for PTLD. We hope to further evaluate thesafety and efficacy of BsAb in PTLD in an ongoing prospective trial."

Post-transplantation • Retrospective data • Review • B Cell Lymphoma • Bone Marrow Transplantation • CNS Disorders • Dermatology • Diffuse Large B Cell Lymphoma • Epstein-Barr Virus Infections • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Pneumonia • Rare Diseases • Respiratory Diseases • Respiratory Syncytial Virus Infections • Solid Organ Transplantation • Transplantation

The time toxicity of CAR-T cell therapy for non-Hodgkin's lymphoma (ASH 2025) - "Patientsreceived axi-cel (32.1%), liso-cel (21.2%), brexu-cel (9.7%), tisa-cel (4.7%) or unspecified CAR-T product(32.4%).Between apheresis and CAR-T administration, patients spent a median of 7 days (IQR 5-11 days) or 23.7%of days with healthcare contact (n=470). Patients receiving CAR-T cell therapy for NHL spent a significant number of days in contactwith the healthcare system, particularly in the first month following administration. Time toxicitylessened over time but patients still spent nearly 20% of their days with healthcare contact in the yearfollowing CAR-T. Outpatient administration was associated with significantly lower time toxicity."

CAR T-Cell Therapy • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma

Impact of bridging therapies prior to CAR T cell therapy for large B-cell lymphoma: Real-world analysis from the cell therapy consortium (ASH 2025) - "Median prior lines of therapy received was 3, with 48% of ptsreceiving axi-cel, 36% tisa-cel, and 16% liso-cel...Among pts who received pola-based BT, 12mo PFS and OS did not differ based on addition of bendamustine to pola (p=0.43).Factors associated with PFS on multivariable analysis (MVA) were elevated LDH pre-LDc (HR 2.3, p<0.01)and receipt of BT (HR 1.5, p<0.01)...In our subgroup analyses, non-chemo BT was associated withsuperior efficacy compared to chemo-based BT, and early institution of HT did not compromise CAR Tefficacy. Exploration of novel BT modalities such as bispecific antibodies are warranted to furtheraugment CAR T outcomes in pts receiving BT."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • B Cell Lymphoma • CNS Disorders • Hematological Malignancies • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party (ASH 2025) - "Final selection included age, sex, presence ofsecondary or transformed disease, number of prior treatment lines, time from diagnosis to infusion, andyear of treatment.ResultsAmong the 2,734 patients included in the analysis, 349 received CAR T-cell therapy (220 axicabtageneciloleucel [axi-cel], 125 tisagenlecleucel, and 4 lisocabtagene maraleucel), and 2,385 underwent auto-HSCT. Both auto-HSCT and anti-CD19 CAR T-celltherapy are associated with favorable outcomes in this setting. While expanding access to CAR T-celltherapy should remain a priority, considering auto-HSCT in this specific subset of patients remains areasonable approach."

CAR T-Cell Therapy • Clinical • B Cell Lymphoma • Bone Marrow Transplantation • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

Naive CD4+ at apheresis and disease control at infusion are associated with improved efficacy in second-line CAR T-cells (ASH 2025) - "Introduction: Second-line (2L) anti-CD19 CAR T-cell therapy (CART) with axicabtagene ciloleucel (axi) orlisocabtagene maraleucel (liso) is standard-of-care for patients (pts) with large B-cell lymphomas (LBCLs)who relapse within 12 months after frontline treatment...Bendamustine was used for lymphodepletion in 89% (axi=83% vsliso=96%, p=0.1)... This is the first real-world study to define clinical and immune correlates of efficacy in 2LCART therapy for LBCL. Both axi and liso are safe and effective. Naïve CD4⁺ T-cell abundance at apheresispredicts long-term outcomes and may serve as a biomarker of T-cell fitness and CART potency.Progressive disease at the time of infusion is associated with inferior response rates and survivaloutcomes, which may be due to less favorable expansion kinetics and T-cell phenotypes."

CAR T-Cell Therapy • Clinical • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • CCR7 • CD4 • CD8

Real-time interleukin-6 (IL-6) kinetics predict cytokine release syndrome (CRS) in patients receiving chimeric antigen receptor (CAR) T-cell therapy for Relapsed/Refractory B-cell malignancies (ASH 2025) - "CAR T-cell products included ciltacabtagene ciloleucel (43%), lisocabtagenemaraleucel (24%), axicabtagene ciloleucel (21%), and brexucabtagene autoleucel (12%). Thirty (71%) ptsreceived lymphodepletion with fludarabine/cyclophosphamide, while 12 (29%) received bendamustine...Theseresults can be integrated into clinical workflows used to identify patients at high risk of CRS and canenable future studies investigating risk-adapted interventions such as preemptive tocilizumab,hospitalization decisions, and toxicity mitigation strategies. Further validation in larger cohorts iswarranted to confirm these findings and inform future practice algorithms."

Clinical • Cytokine release syndrome • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • CRP • IL6 • IL6R

Safety and immunomodulatory effects of siltuximab prophylaxis prior to standard of care CD19 directed chimeric antigen receptor T-cell (CD19.CART) therapy for B-cell lymphomas: Final phase I trial results (ASH 2025) - "CD19.CART product was axicabtageneciloleucel (4 pts), tisagenlecleucel (4), and lisocabtagene maraleucel (2). Siltux was safe as ppx prior to CD19.CART. No gr > 3 CRS occurred and only 1 pt developed gr> 3 ICANS which fully resolved. CD19.CART ORR and CR rate were excellent and responses were durable.In addition, siltux ppx resulted in a favorable phenotypic and functional differentiation of CAR+ T-cellspost-infusion and reduction in cytokines typically associated with CRS/ICANS."

CAR T-Cell Therapy • Clinical • Immunomodulating • P1 data • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • CNS Disorders • Diffuse Large B Cell Lymphoma • Epilepsy • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • B3GAT1 • CCL3 • CD8 • CRP • CXCL10 • GZMB • IFNG • IL15 • IL2 • IL6R • IL7 • TNFA

From response to rupture: Evaluating GI perforation after CD19 CAR‑T in LBCL (ASH 2025) - "Of 398 treated patients, 41 (11%) had radiologic or pathologic evidence of GI involvement at referral. TheGI cohort received axicabtagene ciloleucel (axi-cel) (n=36) or lisocabtagene maraleucel (liso-cel) (n=5).Median age of the cohort was 68 years with 56% males. Majority of cases had DLBCL (63%), IPI ≥3 (51%),and stage IV disease (73%)."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Gastrointestinal Disorder • Hematological Malignancies • High-grade B-cell lymphoma • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Septic Shock